This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Biotech Stock Mailbag: Sarepta, Biomarin, Spark, Raptor

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Sage Psychiatric Drug Shows Activity Hint in Small Muscle Tremor Study

The signal of activity Sage Therapeutics sees with SAGE-547 in essential tremor may turn out to be real or a mirage.

The Numbers Behind Biotech's Horrible, No Good, Awful August

Among all U.S.-listed biotech stocks, regardless of market cap, only 68 companies managed to end August with higher stock prices, while 267 biotech stocks lost ground.

Amicus Acquires Scioderm, Adds Drug for Rare Skin Disorder to Pipeline

Acquiring Scioderm gives Amicus another late-stage orphan disease drug expected to have pivotal trial data in the first half of next year.

Predicting the Outcome of the Biomarin and Sarepta FDA Drug Reviews

Approving both the Biomarin and Sarepta drugs for Duchenne muscular dystrophy is the most politically expedient decision the FDA can make.

An Inside Look at Biotech Investor Pros Dealing With Market Meltdown

Last night, I exchanged emails with a number of investors who run dedicated health care funds. I wanted to know how they navigated Monday's market selloff.

Biotech Stocks Recover From Early-Morning Flash Crash

The iShares Nasdaq Biotechnology Index (IBB), the most closely followed biotech sector index, is down less than 1% after a deep plunge at Monday's open.

Northwest Bio Forced to Temporarily Halt Enrollment of Brain Tumor Vaccine Study (Update)

Enrollment of new patients into the DCVax-L study is suspended until the company "submits certain information from the trial for regulatory review," Northwest Bio said.

Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio

Biotech columnist Adam Feuerstein answers readers' questions about health care.

MannKind Financial Woes Escalate on Failed Debt Settlement

The slow commercial launch of Afrezza, MannKind's inhaled mealtime insulin, continues to be the root cause of the company's balance-sheet woes.

Page 1 of 340
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs